NFE2L2 and hepatocellular carcinoma: Tiliroside, a potent TANK-binding kinase 1 (TBK1) inhibitor, induces ferroptosis via the P62/KEAP1/NRF2 pathway and eventually increases the sensitivity of HCC cells to sorafenib 87.